BioCryst Pharmaceuticals Quarterly Income Statement
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioCryst Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, BioCryst Pharmaceuticals generated $218.3 million in revenue, up 33.6% from the same quarter a year earlier. Net income was $78.4 million (+1441.7% year over year), for a net margin of 35.9% versus a median of 3.1% in the prior 5 quarters. Gross margin was 98.2% (flat year over year) and operating margin 45.1%.
Diluted earnings per share came in at $0.30, up from $0.02.
Summary generated from market data by MetaCap's automated system. Methodology
BioCryst Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 218.25M | 156.41M | 406.56M | 159.40M | 163.35M | 145.53M | 131.53M | 117.08M | 109.33M | 92.76M | 93.40M | 86.74M |
| Revenue growth (YoY) | +33.61% | +7.48% | +209.09% | +36.14% | +49.41% | +56.89% | +40.83% | +34.98% | +32.54% | +34.87% | +17.42% | +14.39% |
| Cost of Revenue | 3.84M | 5.38M | 9.52M | 2.19M | 2.80M | 4.57M | 6.09M | 3.21M | 1.70M | 1.26M | 1.56M | 1.10M |
| Gross Profit | 214.41M | 151.04M | 397.03M | 157.21M | 160.56M | 140.97M | 125.44M | 113.87M | 107.63M | 91.50M | 91.84M | 85.64M |
| Operating Expenses | 115.94M | 852.63M | 136.65M | 127.62M | 130.77M | 119.74M | 129.95M | 106.18M | 98.87M | 105.98M | 134.51M | 97.56M |
| Research & Development | 51.97M | 60.32M | 40.87M | 44.60M | 43.39M | 37.27M | 49.44M | 41.08M | 37.62M | 46.49M | 70.05M | 46.88M |
| Selling, General & Admin | 63.98M | 94.55M | 95.78M | 83.01M | 87.38M | 82.47M | 80.51M | 65.10M | 61.25M | 59.49M | 64.56M | 50.65M |
| Operating Income | 98.47M | -701.60M | 260.38M | 29.59M | 29.79M | 21.23M | -4.51M | 7.69M | 8.76M | -14.49M | -42.67M | -11.92M |
| Interest Expense | 21.71M | 19.78M | 14.13M | 19.66M | 21.58M | 23.49M | 24.45M | 24.83M | 24.73M | 24.51M | 24.58M | 27.34M |
| Other Income (Expense) | -18.99M | -19.21M | -12.37M | -17.46M | -23.30M | -20.47M | -21.48M | -21.14M | -21.26M | -20.53M | — | — |
| Pretax Income | 79.47M | -720.81M | 248.02M | 12.13M | 6.49M | 758.00K | -25.99M | -13.45M | -12.50M | -35.01M | -63.16M | -35.82M |
| Income Tax | 1.08M | 1.00M | 2.17M | -769.00K | 1.40M | 726.00K | 804.00K | 586.00K | 172.00K | 365.00K | -1.43M | 330.00K |
| Net Income | 78.39M | -721.81M | 245.84M | 12.90M | 5.08M | 32.00K | -26.80M | -14.03M | -12.67M | -35.38M | -61.73M | -36.15M |
| Net Income growth (YoY) | +1441.69% | -2255762.50% | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 0.31 | -2.98 | 1.18 | 0.06 | 0.02 | 0.00 | -0.13 | -0.07 | -0.06 | -0.17 | -0.31 | -0.19 |
| EPS (Diluted) | 0.30 | -2.98 | 1.13 | 0.06 | 0.02 | 0.00 | -0.13 | -0.07 | -0.06 | -0.17 | -0.31 | -0.19 |
| Shares Outstanding (Basic) | 254.48M | 242.26M | — | 210.18M | 209.52M | 208.88M | — | 206.91M | 206.43M | 206.06M | — | 189.64M |
| Shares Outstanding (Diluted) | 265.17M | 242.26M | — | 219.88M | 219.89M | 215.26M | — | 206.91M | 206.43M | 206.06M | — | 189.64M |
| EBITDA | 98.98M | -701.14M | 260.78M | 29.93M | 30.11M | 21.56M | -4.20M | 8.00M | 9.08M | -14.18M | -42.25M | -11.50M |
| Gross Margin | 98.24% | 96.56% | 97.66% | 98.63% | 98.29% | 96.86% | 95.37% | 97.26% | 98.45% | 98.64% | 98.33% | 98.73% |
| Operating Margin | 45.12% | -448.55% | 64.05% | 18.56% | 18.23% | 14.59% | -3.43% | 6.57% | 8.01% | -15.62% | -45.68% | -13.74% |
| Net Margin | 35.92% | -461.48% | 60.47% | 8.09% | 3.11% | 2.00% | -20.37% | -11.99% | -11.59% | -38.14% | -66.09% | -41.67% |
This table shows 12 quarterly periods of BioCryst Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BCRX's reporting calendar. What is a income statement?